Lotte Chilsung Beverage (005300) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
23 Jun, 2026Executive summary
Q3 2024 consolidated sales rose 28.3% year-over-year to 10,650 billion KRW, but operating profit fell 6.6% to 787 billion KRW and net profit dropped 34.4% to 445 billion KRW.
For the nine months ended September 30, 2024, consolidated sales reached 31,012 billion KRW, with beverage segment accounting for 79% of sales and 82% of operating profit.
Overseas subsidiary Pepsi-Cola Products Philippines, Inc. (PCPPI) contributed significantly to consolidated results, with notable growth in the Philippines, Pakistan, and Myanmar.
Continued expansion in zero-calorie and health-oriented products, with new launches in both domestic and overseas markets.
Financial highlights
9M 2024 consolidated sales reached 31,012 billion KRW, up 34.5% year-over-year; operating profit was 1,757 billion KRW, down 13.3%.
Gross margin for Q3 2024 was 35.5%, down from 39.9% in Q3 2023; gross margin for 9M 2024 was 34.8%.
Debt-to-equity ratio improved to 174.1% as of September 30, 2024, from 180.7% a year earlier.
Net income attributable to controlling interests for 9M 2024 was 80.7 billion KRW, down from 165.9 billion KRW year-over-year.
Basic EPS (common) for the period was 8,025 KRW.
Outlook and guidance
Targets revenue of 5.5 trillion KRW, ROE of 10–15%, and D/E ratio of 100% or less by 2028.
Aims for a shareholder return rate of 30% or more on a consolidated basis by 2028.
Focus on expanding zero-calorie and health-oriented product lines, strengthening liquor competitiveness, and accelerating overseas growth.
Continued investment in R&D and overseas market expansion, especially in North America and Southeast Asia.
Ongoing cost management and efficiency initiatives to improve profitability.
Latest events from Lotte Chilsung Beverage
- Q2 sales up 38.1% YoY, but net profit and margins fell as overseas drove growth.005300
Q2 202423 Jun 2026 - Q1 2025 revenue and profit declined, with rising debt ratio and segment performance shifts.005300
Q1 202523 Jun 2026 - Profit growth in Q2 2025 driven by overseas and zero-calorie products, with strong full-year outlook.005300
Q2 202523 Jun 2026 - Profits and margins rose in Q3 2025, with overseas and health-focused products driving growth.005300
Q3 202523 Jun 2026 - Q1 2026 delivered sharp profit gains, margin expansion, and robust overseas segment growth.005300
Q1 202622 Jun 2026 - Domestic sales and profits fell in Q4 2025, but overseas growth and 2026 recovery are forecast.005300
Q4 20251 Apr 2026 - Record sales in 2024 offset by profit decline; 2025 targets strong growth and margin recovery.005300
Q4 20245 Jun 2025